He Yuan Li Ji and Huicun Medical have established a deep strategic partnership, joining forces to drive high-quality development in the field of biological sample storage.

On February 22, 2024, HeYuan Li Ji (Shanghai) Biotechnology Co., Ltd., a wholly owned subsidiary of HeYuan Bio, announced the signing of a strategic partnership with Shanghai Huicun Medical Technology Co., Ltd. (“Huicun Medical”). The two parties have reached a high degree of alignment on product development and market expansion in the fields of tissue and cell preservation and transportation, aiming to accelerate innovation in biobank storage and logistics solutions and to promote the high-quality development of the cell and gene therapy sectors.

(Attendees from both sides at the signing ceremony that day)

The two parties have reached a deep strategic partnership.

Wang Fujie, Deputy General Manager of HeYuan Bio, stated: “The strategic partnership between HeYuan Li Ji and Huicun Medical marks a significant milestone for HeYuan Li Ji as it embarks on a strong start to 2024. Moving forward, the two parties will expand their collaborative horizons, further enhance their products and services, spearhead innovation in bio‑sample storage and transportation solutions, and contribute even more to the cell and gene therapy sectors.”

Yan Hexin, General Manager of Huicun Medical, stated: “Heyuan Liji is a controlling subsidiary of Heyuan Bio (stock code: 688238), focusing on the R&D, manufacturing, and sales of life-science products. We are delighted to have established a strategic partnership with Heyuan Liji. Huicun Medical has accumulated years of expertise in biological sample cryopreservation and live tissue transportation, with several products—including cell cryopreservation solutions and tissue‑transport protective solutions—matching or surpassing comparable imported offerings. The two companies enjoy strong alignment along the industry value chain, offering ample opportunities for collaboration. This partnership will accelerate the integration of our respective capabilities, enabling us to deliver even better products to our customers.”

Li Ruibiao, General Manager of Heyuan Liji, stated: “Huicun Medical is a well‑known, versatile, innovative enterprise integrating manufacturing, R&D, and sales, with mature technologies for the transport and preservation of cells and tissues. Cell culture, cell transfection, cell analysis, and cell storage constitute key product lines for Heyuan Liji. We are delighted to deepen our collaboration, and in the future we will fully leverage the strengths of both parties’ technological platforms and product portfolios to jointly drive progress, comprehensively empower the development of the life sciences industry, and accelerate the domestic substitution of reagents in the fields of cell and tissue transport and preservation.”

About HeYuan Bio

HeYuan Bio (stock code: 688238), founded in 2013, is a biotechnology company focused on the field of gene therapy. It provides CRO services—including the development of gene‑therapy vectors and gene‑function studies—to support basic research in gene therapy, as well as CDMO services—such as process development and testing, IND‑CMC pharmaceutical studies, and GMP‑compliant clinical‑sample production—for the R&D of gene‑therapy products, including recombinant viral vector therapeutics, oncolytic viruses, and CAR‑T cell therapies. Guided by the mission “Empowering Gene Therapy, Safeguarding Life and Health,” with gene‑therapy vector R&D and manufacturing at its core, the company remains committed to a customer‑centric approach and delivering expert services. It aims to become an internationally leading CXO group in gene and cell therapy, accelerating progress across basic research, drug discovery, pharmaceutical studies, clinical trials, and commercialization, thereby driving the advancement of the gene‑therapy industry and improving human health.

About He Yuan Li Ji

HeYuan Li Ji (Shanghai) Biotechnology Co., Ltd. was established in 2023 as a wholly owned subsidiary of HeYuan Bio (stock code: 688238). It is a domestic bioreagent company integrating R&D, manufacturing, and sales, with a strong focus on the life sciences and biotechnology sectors. The company is committed to providing customers with cutting-edge, user-friendly, and cost-effective reagent products, covering experimental reagents and kits for cell biology, molecular biology, immunology, and biochemistry.

At present, we have authorized agents in more than 40 cities nationwide and directly serve thousands of end‑users, including CROs, pharmaceutical companies, universities, hospitals, and research institutes. Li Ji’s products have helped our customers publish hundreds of SCI‑indexed papers, including numerous articles in the prestigious CNS journals.

About Huicun Medical

Shanghai Huicun Medical Technology Co., Ltd. was founded in Zhangjiang Science City. As an innovative cell‑drug R&D enterprise rooted in the field of regenerative medicine, the company is dedicated to providing cutting‑edge cellular therapies for patients with moderate to severe liver disease. It has pioneered the development of an original small‑molecule reprogramming platform, overcoming key scientific challenges and technical bottlenecks in maintaining the functional integrity and scaling up the culture of human hepatocytes in vitro. This breakthrough ensures a reliable source of hepatocytes for clinical applications such as hepatocyte transplantation and bioartificial liver support. Guided by the corporate mission “Awakening Regeneration, Saying Goodbye to Transplantation,” the company remains steadfastly committed to delivering lasting solutions to the global burden of liver disease.

Based on R&D needs, the company has developed multiple proprietary patented technologies in the storage and transportation of cell and tissue samples, with some products matching or surpassing comparable imported counterparts.